CVRx, Inc.

Contributing Author

Recent Articles by CVRx, Inc.

10 hours	CVRx Responds to Letter from Pointillist Family Office CVRX +6.98% GlobeNewswire
Aug-24	CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy CVRX +10.92% GlobeNewswire
Aug-11	CVRx Announces Sales Leadership Transition CVRX +9.70% GlobeNewswire
Aug-06	CVRx Reports Second Quarter 2026 Financial and Operating Results CVRX +6.45% CVRX -59.76% GlobeNewswire
Aug-06	CVRx Reports Second Quarter 2026 Financial and Operating Results CVRX +6.45% CVRX -59.76% GlobeNewswire
Jul-28	CVRx to Present at Canaccord Genuity's 46th Annual Growth Conference CVRX GlobeNewswire
Jul-23	CVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026 CVRX GlobeNewswire
Jun-09	CVRx Announces Chief Financial Officer Transition CVRX GlobeNewswire
May-27	CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference CVRX GlobeNewswire
May-20	CVRx to Present at the William Blair 46th Annual Growth Stock Conference CVRX GlobeNewswire
May-14	CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy CVRX +9.96% GlobeNewswire
May-11	CVRx Reports First Quarter 2026 Financial and Operating Results CVRX CVRX -23.84% GlobeNewswire
May-04	CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population CVRX GlobeNewswire
Apr-27	CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026 CVRX GlobeNewswire
Apr-20	CVRx Announces Nomination of Michael Dale for Election to the Board of Directors CVRX GlobeNewswire
Apr-13	CVRx Reports Preliminary First Quarter 2026 Financial Results CVRX +9.15% GlobeNewswire
Mar-02	CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting CVRX GlobeNewswire
Feb-12	CVRx Reports Fourth Quarter and Full Year 2025 Financial and Operating Results CVRX -6.41% CVRX -13.01% GlobeNewswire
Jan-29	CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026 CVRX GlobeNewswire
Jan-22	CVRx Announces Initiation of BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population CVRX +8.61% CVRX +11.43% GlobeNewswire
Jan-12	CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 Guidance CVRX -9.86% GlobeNewswire
Jan-06	CVRx Announces Implementation of New Category I CPT Codes for Barostim Therapy CVRX GlobeNewswire
Dec-22	CVRx to Present at the 44th Annual J.P. Morgan Healthcare Conference CVRX GlobeNewswire
Nov-19	CVRx to Participate at the Piper Sandler 37th Annual Healthcare Conference CVRX GlobeNewswire
Nov-05	CVRx Reports Third Quarter 2025 Financial and Operating Results CVRX GlobeNewswire
Nov-04	CVRx to Present at the Jefferies Global Healthcare Conference in London CVRX GlobeNewswire
Oct-22	CVRx to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call on Nov. 5, 2025 CVRX GlobeNewswire
Aug-04	CVRx Reports Second Quarter 2025 Financial and Operating Results CVRX CVRX -9.87% GlobeNewswire
Jul-29	CVRx to Present at the Canaccord Genuity 45th Annual Growth Conference CVRX GlobeNewswire
Jul-21	CVRx to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call on August 4, 2025 CVRX GlobeNewswire
Jul-16	CVRx Announces Positive News on Outpatient Payment for Barostim CVRX +19.01% GlobeNewswire
May-28	CVRx to Present at the William Blair 45th Annual Growth Stock Conference CVRX GlobeNewswire
May-08	CVRx Reports First Quarter 2025 Financial and Operating Results CVRX CVRX -38.69% GlobeNewswire

CVRx, Inc.

Recent Articles by CVRx, Inc.

Upgrade your Finviz experience